EPA Defends Glyphosate Safety For Bayer, As Roundup Juries Continue to Find Weedkiller Causes Cancer

|

In a move that is likely to cause even more controversy than resolution, federal regulators have rushed to the defense of the controversial weedkiller Roundup, saying that the active ingredient glyphosate is not a cancer-causing agent, despite a number of independent studies published in recent years, and internal memos obtained by the manufacturer that suggest Monsanto has exerted undue influence over the regulators, in what appeared to be an uncomfortably close relationship.

On April 23, the U.S. Environmental Protection Agency (EPA) released a โ€œProposed Interim Registration Review Decisionโ€ (PDF) on glyphosate, reiterating an earlier conclusion that the herbicide is not a carcinogen. The decision also answers public comments submitted since the agency’s original determination, defending its evaluation methods.

In 2015, the World Health Organizationโ€™s International Agency for Research on Cancer (IARC) announced that glyphosate is likely a cancer-causing agent. In particular, the IARC report linked the side effects of Roundup and other glyphosate-based herbicides with an increased risk of non-Hodgkinโ€™s lymphoma.

Roundup-Cancer-Lawsuit-Lawyer
Roundup-Cancer-Lawsuit-Lawyer

In September 2016, the EPA disputed that finding, maintaining that the herbicide was safe and not a cancer-causing agent. The EPA continued to defend that decision in this latest review decision.

โ€œThe agency used the most current science policies and risk assessment methodologies to prepare a risk assessment in support of the registration review of glyphosate,โ€ the review states. โ€œThe EPA thoroughly asses risks to humans from exposure to glyphosate from all uses and all routes of exposure and did not identify any risks of concern.โ€

However, the position of the EPA has been brought into question following the release of documents during ongoing litigation over Roundup, known as the โ€œMonsanto Papersโ€, which many say show an inappropriate relationship between Monsanto and EPA, as well European regulators. In some instances, EPA personnel have boasted about squashing glyphosate safety reviews in the past.

At one point, former EPA official Jess Rowland reassured Monsanto that there would be no pesticide review for glyphosate, saying he should โ€œget a medalโ€ for protecting the companyโ€™s product, according to documents revealed as part of the ongoing litigation.

Bayer and itโ€™s recently-acquired subsidiary, Monsanto, currently face more than 13,000ย Roundup lawsuitsย brought by farmers, landscapers, and other consumers diagnosed with cancer following exposure to the controversial weedkiller.

In March, the first federal bellwether caseย ended in an $80 million verdict, after the jury found that Roundup was a substantial cause of the plaintiffโ€™s non-Hodgkinโ€™s lymphoma. Before that, a California state court jury reached a similar conclusion, resulting in a $78 million verdict for a former school groundskeeper diagnosed with cancer.

Another California trial is currently underway, where a jury is considering evidence about the link between glyphosate and cancer in aa lawsuit brought by a husband and wife who were each diagnosed with non-Hodgkins lymphoma following exposure to Roundup. The couple was granted an expedited trial date since they are both dying from the cancer, and the jury is expected to return within the next few weeks.

Despite the EPA assurances, a number of local governments and other countries are continuing to push for a ban on Roundup, and the safety of glyphosate remains in serious doubt in the minds of many independent experts.

Irvin Jackson
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Image Credit: Photo Courtesy of <a href="https://www.flickr.com/photos/jeepersmedia/14874003257/in/photolist-oEn9Y2-oEmvHy-bTWHFx-nfCdLV-r4HEKx-rnWS2S-r6sFqE-p2qQKx-oZp21Q-p2arLx-oZoYWu-p2qRNe-oZp1K9-oWzFf8-oJWeBo-oWPq8C-p2oWDC-oJWGji-oEmb2Z-oWRdiz-GJW4pR-GGDZ27-a9RCv2-qrg4mF-rnV1kP-fwZmz-2sscR9-oe3oMa-sboouE-7Q9sz-auohod-rbkbaM-dykaWR-HadKLC-rnUQ6F-r4HT7B-rkKbUm-qr3DSm-qr3t6G-r6sNDC-qr3A3h-9Kvo44-5XtM3N-ey91rF-oe3ovi-8XXkwu-odYLgh-nWy2oy-ofPpbP-odSXiw">Mike Mozart via Flickr</a> Creative Commons



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

The first Bard PowerPort lawsuit bellwether trial commences next week involving claims that a man suffered a severe infection due to the port catheter’s allegedly defective design.